Study of ZIO-201 in Advanced Sarcoma

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Sarcoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Santa Monica, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Metastatic and /or unresectable disease state after previous standard chemotherapy

Treatment and study plan

ZIO-201

Drug

ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months

Primary outcomes

toxicities

Time frame: 6 months

Secondary outcomes

pharmacokinetics

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Alaunos Therapeutics

Industry

Registry information

Official study title

A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2013
First posted: Feb 26, 2007
Registry last updated: Jan 31, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed